Neuberger Berman Group LLC Allogene Therapeutics, Inc. Transaction History

Neuberger Berman Group LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$13.13 - $24.52 $106,156 - $198,244	-8,085 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$23.49 - $35.8 $191,701 - $292,163	-8,161 Reduced 50.23%	8,085 $211,000
Q1 2021 May 13, 2021	SELL	$25.79 - $39.02 $14,313 - $21,656	-555 Reduced 3.3%	16,246 $574,000
Q4 2020 Feb 10, 2021	BUY	$25.24 - $43.45 $22,488 - $38,713	891 Added 5.6%	16,801 $431,000
Q3 2020 Nov 12, 2020	BUY	$32.38 - $44.96 $53,427 - $74,184	1,650 Added 11.57%	15,910 $599,000
Q2 2020 Aug 13, 2020	BUY	$18.39 - $54.04 $12,137 - $35,666	660 Added 4.85%	14,260 $610,000
Q1 2020 May 14, 2020	BUY	$18.22 - $28.25 $247,791 - $384,200	13,600 New	13,600 $264,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.